The contribution of DNA-methylation based gene silencing to carcinogenesis is well
established. Increasingly, DNA-methylation is examined using genome-wide techniques …

Background: Lower levels of genomic DNA methylation in blood DNA has been associated
with risk of different cancers and several cancer risk factors. To understand the use of …

The malignant transformation of normal cells is driven by both genetic and epigenetic
changes. With the advent of next-generation sequencing and large-scale international …

The spatial arrangement and three-dimensional structure of DNA in the nucleus is controlled
through the interdigitation of DNA binding proteins such as histones and their modifiers, the …

Circulating tumor DNA in plasma and serum has been demonstrated to reflect the biological
characteristics of tumors, including the rates of apoptosis and necrosis. Aberrant promoter …

Cancer cells display widespread genetic and epigenetic abnormalities, but the contribution
to disease risk, particularly in normal tissue before disease, is not yet established. Genome …

Cancer-specific DNA methylation from the tumor derived fraction of cell free DNA found in
blood samples could be used for minimally invasive detection and monitoring of cancer. The …

In cancer, epigenetic changes such as covalent addition of methyl groups to the genomic
DNA itself are more prominent than genetic changes. Cytosine–phosphate–guanosine …

One plausible mechanism for the environment to alter cancer susceptibility is through DNA
methylation. Alterations in DNA methylation can lead to genomic instability and altered gene …

Cell-free circulating DNA carries not only tumor-specific changes in its sequence but also
distinctive epigenetic marks, namely DNA methylation, in certain GC-rich fragments. These …